MEDIF - MediPharm Labs Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
4.8725
+0.0825 (+1.72%)
As of 11:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.7900
Open4.7700
BidN/A x N/A
AskN/A x N/A
Day's Range4.6900 - 4.9400
52 Week Range0.9125 - 5.6500
Volume99,703
Avg. Volume348,429
Market Cap558.798M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire19 hours ago

    UPDATE - New York City Icahn School of Medicine at Mount Sinai and Renowned Global Researcher Dr. Hurd, Select MediPharm Labs to Support 500 Patient Major Clinical Study And “CBD International Consortium” to Develop Treatment of Opioid Addiction

    MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce it has been selected by the Icahn School of Medicine at Mount Sinai Hospital, New York City (“Icahn School of Medicine”), to participate in a clinical trial dedicated to developing a non-addictive oral gelcap medication for the treatment of opioid use disorder through anti-anxiety intervention utilizing hemp-derived CBD combined with a proprietary formula (the “Formula”). This will be a U.S. and international large-scale, multi-site clinical trial that will include at least 500 patients spanning the United States, Canada, Australia, Europe and Jamaica.

  • GlobeNewswire2 days ago

    New York City Ichan School of Medicine at Mount Sinai and Renowned Global Researcher Dr. Hurd, Select MediPharm Labs to Support 500 Patient Major Clinical Study and “CBD International Consortium” to Develop Treatment of Opioid Addiction

    MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce it has been selected by The Mount Sinai Hospital, New York City (“Mount Sinai”), to participate in a clinical trial dedicated to developing a non-addictive oral gelcap medication for the treatment of opioid use disorder through anti-anxiety intervention utilizing hemp-derived CBD combined with a proprietary formula (the “Formula”). This will be a U.S. and international large-scale, multi-site clinical trial that will include at least 500 patients spanning the United States, Canada, Australia, Europe and Jamaica.

  • GlobeNewswire3 days ago

    MediPharm Labs Australia Awarded Cannabis Manufacturing Licence From Office of Drug Control – Establishes Asia-Pacific Foothold

    MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that its subsidiary, MediPharm Labs Australia Pty. Ltd. (“MediPharm Labs Australia”), has received its cannabis manufacturing licence (the “Licence”) from the Australian Office of Drug Control under the Narcotics Drugs Act 1967  on May 21, 2019. This is a significant milestone for MediPharm Labs that establishes the Company as an early mover in the Australian cannabis industry. In addition, MediPharm Labs Australia is expected to provide the Company with a global supply chain platform and a foothold in the Asia-Pacific region.

  • GlobeNewswire3 days ago

    MediPharm Labs Announces Addition to $1.2B MJ ETFMG Alternative Harvest ETF (USA)

    TORONTO, May 21, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and.

  • GlobeNewswire7 days ago

    Emerald Health Therapeutics Introduces Unique Premium CBD Oil SYNC 25 to British Columbia Recreational Marketplace

    VANCOUVER, British Columbia, May 17, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has shipped 6,000 40 ml units of its SYNC 25 CBD oil to the.

  • GlobeNewswire9 days ago

    MediPharm Labs Signs Committed Term Sheet for $20 Million Debt Facility With Schedule 1 Bank

    MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc. (“MediPharm”), has signed a committed term sheet for a $20 million senior secured revolving credit facility ("Credit Facility") from a Canadian Schedule 1 Bank.  The Credit Facility is intended to provide MediPharm Labs access to non-dilutive capital to fund planned growth, as well as for general corporate and working capital purposes. The Credit Facility consists of a $15 million operating loan with a one-year term and a $5 million non-revolving equipment term loan with a three-year term. The Credit Facility, once closed, will bear interest at the Schedule 1 Bank’s prime lending rate plus 1.85% per annum.

  • MarketWatch10 days ago

    Cronos, MediPharm enter supply deal for private-label cannabis concentrate

    Cronos Group Inc. announced Tuesday a supply deal with MediPharm Labs Corp. , in which MediPharm will supply Cronos with about C$30 million ($22.3 million) of private label cannabis concentrate over 18 months. With certain renewal and purchase options, the deal could potential reach C$60 million over 24 months. The U.S.-listed shares of Cronos rose 3.1% premarket, while MediPharm's stock was still inactive. The companies have also entered into a multi-year tolling agreement, in which Cronos will supply bulk cannabis to MediPharm's extraction facility, to fulfill certain processing needs. "As the industry develops and matures, we see opportunity to work with companies like MediPharm Labs that provide specialized, high-quality services and inputs for our products," said Cronos Chief Executive Mike Gorenstein. Cronos's stock has rallied 37.2% year to date through Monday and MediPharm shares have rocketed nearly 4-fold (280%), while the ETFMG Alternative Harvest ETF has climbed 30.4% and the S&P 500 has gained 12.2%.

  • GlobeNewswire10 days ago

    Cronos Group and MediPharm Labs Enter $30 Million Multi-Year Private Label Cannabis Concentrate Supply Agreement with Potential to Increase to $60 Million

    MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has entered into a multi-year supply agreement with Cronos Group Inc. (CRON) (CRON) (“Cronos Group”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months.  In addition, Cronos Group has selected MediPharm Labs’ state of the art extraction facility in Barrie, Ontario, as a preferred partner to fulfill certain of its processing needs, under a separate tolling arrangement.

  • GlobeNewswire10 days ago

    Cronos Group and MediPharm Labs Enter Cannabis Concentrate Supply Agreement

    Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), is pleased to announce that it has entered into a multi-year supply agreement with MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months.

  • Benzinga14 days ago

    MediPharm Labs Revenue Rises 115% Quarter-Over-Quarter

    MediPharm Labs Corp. (OTC: MEDIF ) announced first-quarter financial results Friday. The global extraction, distillation, purification and cannabinoid isolation company generated revenue of $22 million, ...

  • GlobeNewswire14 days ago

    MediPharm Labs Announces Q1 2019 Revenue of $22 Million and Adjusted EBITDA of $4.3 Million

    TORONTO, May 10, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven.

  • GlobeNewswire16 days ago

    MediPharm Labs Sets Date to Release First Quarter 2019 Financial Results

    TORONTO, May 08, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven.

  • GlobeNewswire22 days ago

    MediPharm Labs Announces Upgrade to the OTCQX Best Market in the U.S. Under Symbol “MEDIF”

    TORONTO, May 02, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven.

  • OTC Markets Group Welcomes MediPharm Labs Corp. to OTCQX
    PR Newswire22 days ago

    OTC Markets Group Welcomes MediPharm Labs Corp. to OTCQX

    NEW YORK , May 2, 2019 /PRNewswire/ --   OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced MediPharm Labs Corp.  (TSX-V: LABS ; ...

  • GlobeNewswire23 days ago

    MediPharm Labs Appoints Renowned Medical Expert and Pharmaceutical Researcher Dr. Paul Tam to its Board of Directors

    MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce the appointment of Dr. Paul Tam, MBBS, FRCP(C), FACP to its Board of Directors effective immediately, subject to the necessary regulatory approvals. In connection with the Company’s goal of satisfying non-venture requirements for corporate governance and financial oversight, Dr. Tam will also replace Chris Hobbs on the Company’s Audit Committee resulting in an Audit Committee fully comprised of independent directors in accordance with National Instrument 52-110 – Audit Committees. “Dr. Paul Tam is a tremendous addition to our board and will be a valuable independent director and contributor as we continue to deepen our medical expertise through this next phase of growth,” said Patrick McCutcheon, Chief Executive Officer, MediPharm Labs.

  • GlobeNewswire25 days ago

    MediPharm Labs Appoints Former Johnson & Johnson Group Product Director as Chief Strategy Officer

    TORONTO, April 29, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven.

  • Newsfile29 days ago

    MediPharm Labs Executing on International Cannabis Extracts Strategy -- CFN Media

    Seattle, Washington--(Newsfile Corp. - April 25, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing MediPharm Labs and its plans for global expansion.Canadian companies have a bit of a head start on those from other countries where the legal cannabis framework is not as comprehensive or advanced. In many ways, countries around the globe look ...

  • GlobeNewswirelast month

    MediPharm Labs Announces DTC Eligibility, Increasing Accessibility for US Investors

    MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce it has received Depository Trust Company (DTC) eligibility for its common shares in the United States. “DTC eligibility” simplifies the process of trading and transferring the Company’s common shares between brokerages in the U.S. “We are pleased that MediPharm Labs common shares are now considered to be “DTC Eligible”, to facilitate the trading of our common shares in the U.S. markets”, said Patrick McCutcheon, Chief Executive Officer, MediPharm Labs.

  • GlobeNewswirelast month

    MediPharm Labs Announces OTC Ticker Symbol Change to “MEDIF”

    TORONTO, April 09, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven.